The potential to use reduced dosing was one of the controversial issues at IAS 2025 with conflicting conclusion from two late-breaker studies.
A systematic review and meta-analysis of eight studies using 5, 4 or 3 compared to 7 daily doses each week found this to be both safe and effective. This study was to look at a potential crisis response to sudden cuts in PEPFAR and USAID funding. Results were presented by Cassie Fairhead from the Royal Free Hospital in London.
Read the full news story at HIV i-Base.
All HIV i-Base reports from IAS 2025 can be accessed here.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.